MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis

Jianwei Xu; Tianxiao Wang; Zhe Cao; Hua Huang; Jian Li; Wenjing Liu; Shanglong Liu; Lei You; Li Zhou; Taiping Zhang; Yupei Zhao

doi:10.18632/oncotarget.2184

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis

Jianwei Xu, Tianxiao Wang, Zhe Cao, Hua Huang, Jian Li, Wenjing Liu, Shanglong Liu, Lei You, Li Zhou, Taiping Zhang _ and Yupei Zhao

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2014; 5:6983-6993. https://doi.org/10.18632/oncotarget.2184

Metrics: PDF 2736 views | HTML 2693 views | ?

Abstract

Jianwei Xu1,*, Tianxiao Wang2,*, Zhe Cao1, Hua Huang1, Jian Li1, Wenjing Liu1, Shanglong Liu1, Lei You1, Li Zhou1, Taiping Zhang1, Yupei Zhao1

1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of head and neck Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China

* These authors contributed equally to this work

Correspondence:

Taiping Zhang , email:

Yupei Zhao , email:

Keywords: pancreatic cancer, miRNA, chemoresistance, prognosis

Received: May 06, 2014 Accepted: July 06, 2014 Published: July 08, 2014

Abstract

Chemoresistance is one of the causes of poor prognosis in pancreatic cancer patients. However, the mechanisms of resistance remain unclear. Here we screened miRNAs associated with drug resistance in pancreatic cancer, and identified a panel of miRNAs dysregulated in gemcitabine-resistance pancreatic cancer cells, including 13 downregulated miRNAs and 20 upregulated miRNAs. Further studies focusing on miR-497 demonstrated that miR-497 suppressed cells proliferation, decreased the percentage of S phase cells, re-sensitized cells to gemcitabine and erlotinib, and attenuated migration and invasion capacities. Furthermore, fibroblast growth factor 2 and fibroblast growth factor receptor 1 were confirmed as miR-497 targets. Overexpression of miR-497 inhibited tumor growth in vivo. Additionally, miR-497 expression was significantly downregulated in pancreatic cancer tissues compared with tumor-adjacent samples (P=0.000). Low expression of miR-497 was an independent adverse prognostic factor of pancreatic cancer (P=0.01, hazard ratio=2.762, 95% confidence interval: 1.159–6.579). Together these results indicate that miR-497 could be a new therapeutic target and prognostic marker of pancreatic cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2184

Publication Alerts

Research Papers:

MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis

Abstract